HK Stock MarketDetailed Quotes

HENGRUI PHARMA (01276)

Watchlist
  • 66.800
  • -1.000-1.47%
Trading Apr 21 13:03 CST
443.36BMarket Cap51.94P/E (TTM)

About HENGRUI PHARMA Company

Founded in 1970, the company was listed on the Shanghai Stock Exchange in 2000 and on the Hong Kong Stock Exchange in 2025, becoming an A+H share–listed enterprise. As an innovative, global pharmaceutical company dedicated to the research, development, manufacturing, and marketing of high-quality medicines, the company remains steadfast in its patient-centric mission, focusing on oncology, metabolic and cardiovascular diseases, immune and respiratory disorders, and neuroscience. It continuously pursues breakthroughs in drug discovery and development, striving to conquer diseases, enhance quality of life, and extend lifespan by expanding the frontiers of what is possible and leveraging the power of science and technology to benefit patients worldwide. The company's core business encompasses the R&D, production, and sales of pharmaceutical products. Its key products include Pyrrotinib Maleate Tablets, Carrelizumab for Injection, Rivirumab Tablets, Haquoparib Ethanolamine Tablets, Darzalex Hydroxyethyl Sulfonate Tablets, and Iohexol Injection, among others. The company has received numerous accolades, including the "Environmental Protection Model Enterprise" designation and the Jiangsu Province "Green Development Leader" award. In 2023, it was honored with the Lianyungang Economic and Technological Development Zone's "Environmental Protection Quality Award," recognized as one of the first batch of "Sterile Drug Quality Assurance Enterprises" by the China Association for Pharmaceutical Quality Management, and awarded the title of "Outstanding Pharmaceutical Quality Management Enterprise in Jiangsu Province" by the Jiangsu Provincial Pharmaceutical Quality Management Association. Additionally, the company's "Chuying QC Group" and "Yuanzhi QC Group" have been recognized as outstanding groups for quality control (QC) presentations and exchanges within the Jiangsu pharmaceutical industry, as well as recipients of the Jiangsu Province "Green Development Leader" award, the Best Presentation Award, and first- and second-class awards from national, provincial, and municipal quality associations for their exceptional achievements.

Company Profile

Symbol01276
Company NameHENGRUI PHARMA
ISINCNE100006XS6
Listing DateMay 23, 2025
Issue Price44.05
Shares Offered224.52M share(s)
FoundedApr 28, 1997
Registered AddressChina
Chairmanpiaoyang sun
Secretaryyingxianliuxiaohan liang
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 38, Huanghe Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province, China
Head Office and Principal Place of BusinessRoom 1920, 19th Floor, Lee Gardens One, 33 Hysan Drive, Causeway Bay, Hong Kong, China
Fiscal Year Ends12-31
Employees20602
MarketHong Kong motherboard
Phone021-61053323
Fax021-61063801
Emailir@hengrui.com
Websitehttps://www.hengrui.com
BusinessManufacture of tablets (including anti-tumor drugs), oral solutions, suspensions, sterile active pharmaceutical ingredients (anti-tumor drugs), active pharmaceutical ingredients (including anti-tumor drugs), psychotropic substances, soft capsules (including anti-tumor drugs), lyophilized powder for injection (including anti-tumor drugs), powder for injection (anti-tumor drugs and cephalosporins), inhalation dry-powder inhalers, oral suspensions, oral emulsions, large-volume injectables (including multilayer co-extruded infusion bags and anti-tumor drugs), small-volume injectables (including anti-tumor drugs and non-terminal sterilized products), bioengineered products (polyethylene glycol–recombinant human granulocyte colony-stimulating factor injection), hard capsules (including anti-tumor drugs), granules (anti-tumor drugs), dry-powder inhalers, film preparations, gel preparations, and cream preparations; pre-processing and extraction of traditional Chinese medicines; research, development, manufacturing, and sales of medical devices; sales of general chemical products; self-operated and agency import and export of various goods and technologies, except for those goods and technologies whose import and export are restricted or prohibited by the state; research, development, manufacturing, and sales of pharmaceutical packaging materials and pharmaceutical packaging products.

Company Executives

  • Name
  • Position
  • Salary
  • piaoyang sun
  • Chairman, Executive Director, Chair of the Strategy Committee
  • 2.02M
  • hongbin dai
  • Vice Chairman, Executive Director, Members of the Compensation and Assessment Committee, Members of the Strategic Committee
  • 8.20M
  • ji feng
  • Executive Director, General Manager (President), Chief Operating Officer, Nomination Committee Members
  • 8.32M
  • lianshan zhang
  • Executive Vice President, Executive Director, Members of the Strategic Committee
  • 7.20M
  • ningjun jiang
  • Executive Vice President, Executive Director, Chief Strategy Officer, Members of the Strategic Committee, Authorized Representative
  • 7.61M
  • jieping sun
  • Executive Director, Senior Vice President, Employee Representative Director
  • 4.06M
  • congzhao guo
  • Non-executive Director, Members of the Strategic Committee
  • --
  • liguang lou
  • Independent Non-Executive Director, Members of the Strategic Committee, Audit Committee Members
  • --
  • qingsheng ceng
  • Independent Non-Executive Director, Chair of the Audit Committee, Nomination Committee Members, Members of the Compensation and Assessment Committee
  • --
  • jinyun sun
  • Independent Non-Executive Director, Chair of the Compensation and Assessment Committee, Chair of the Nomination Committee, Audit Committee Members
  • --
  • jien zhou
  • Independent Non-Executive Director, Audit Committee Members
  • --
  • guoxin zhu
  • Senior Vice President
  • --
  • jianjun liu
  • Chief Financial Officer
  • --
  • xiaohan liu
  • Joint Company Secretary, Board Secretary
  • --
  • yingxian liang
  • Joint Company Secretary, Authorized Representative
  • --
Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 -1.92%
Sample Name
Sample Code
 -3.26%
Sample Name
Sample Code
 -8.89%
4
CHINA OILFIELD
02883
-8.95%
5
SHANGHAI PECHEM
00338
-9.49%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +30.08%
Sample Name
Sample Code
 +20.33%
Sample Name
Sample Code
 +18.58%
4
Business-intelligence Of Oriental Nations Corporation
300166
+11.17%
5
INESA Intelligent Tech Inc.
600602
+10.63%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -